Patents Examined by Christina Borgeest
  • Patent number: 9950125
    Abstract: The present invention provides compositions and methods for treating a subject in need of treatment with testosterone, including introducing testosterone into the subject subcutaneously, intradermally, or intramuscularly, from a needle assisted jet injection device.
    Type: Grant
    Filed: April 5, 2013
    Date of Patent: April 24, 2018
    Assignee: ANTARES PHARMA, INC.
    Inventors: Paul K. Wotton, Kaushik J. Dave, John W. Hayes, Peter L. Sadowski, Hermanus L. Jooste, Jonathan Jaffe
  • Patent number: 9803012
    Abstract: The present invention provides compositions and methods useful for regulating fertilization and for use as a contraceptive based on the discovery herein of an oocyte specific protein, SAS1R (Sperm Acrosomal SLLP1 Receptor), which is a sperm protein receptor. Six SAS1R variants, including the full length SAS1R, were identified. mSLLP1 and SAS1R co-localized to oocytes and to acrosomes of acrosome-reacted sperm. Interactions between mSLLP1 and SAS1R were demonstrated by far-western analysis, in a yeast two-hybrid system under stringent selection conditions, and by immunoprecipitation of SAS1R by anti-mSLLP1 as well as the converse. Purified recombinant SAS1R was found to have protease activity, to inhibit fertilization in-vitro, and to induce an immune response in females.
    Type: Grant
    Filed: May 23, 2012
    Date of Patent: October 31, 2017
    Assignee: UNIVERSITY OF VIRGINIA PATENT FOUNDATION
    Inventors: John C. Herr, Monika Sachdev, Arabinda Mandal
  • Patent number: 9795653
    Abstract: A use of an inhalable powder formulation for preventing or treating an NMDA receptor hypofunction-related disease, a method for preventing or treating an NMDA receptor hypofunction-related disease in a subject, which comprises administering a therapeutically effective amount of an inhalable powder formulation comprising growth hormone (GH) to the subject in need thereof, and an inhalable powder formulation for preventing or treating an NMDA receptor hypofunction-related disease comprising GH as an active ingredient are provided.
    Type: Grant
    Filed: February 14, 2014
    Date of Patent: October 24, 2017
    Assignee: MediGeneBio Corporation
    Inventors: Sy Lee, Sung-Ick Park
  • Patent number: 9795637
    Abstract: The present invention relates to the use of umbilical cord blood cells from a donor or patient to provide neural cells which may be used in transplantation. The isolated cells according to the present invention may be used to effect autologous and allogeneic transplantation and repair of neural tissue, in particular, tissue of the brain and spinal cord and to treat neurodegenerative diseases of the brain and spinal cord.
    Type: Grant
    Filed: October 9, 2012
    Date of Patent: October 24, 2017
    Assignees: University of South Florida, Saneron CCEL Therapeutics, Inc.
    Inventors: Paul R. Sanberg, Juan Sanchez-Ramos, Alison Willing, Daniel D. Richard
  • Patent number: 9766253
    Abstract: The present invention relates to the diagnosis of acquired sensory neuronopathies (SNN), and to the treatment of these disorders.
    Type: Grant
    Filed: June 28, 2013
    Date of Patent: September 19, 2017
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique, Universite Jean Monnet, Universite Claude Bernard Lyon 1, Hospices Civils de Lyon, Centre Hospitalier Universitaire de Saint Etienne
    Inventors: Jerome Marc Claude Honnorat, Jean-Christophe Antoine, Jean-Philippe Camdessanche, Nadia Boutahar, Veronique Annie Rogemond
  • Patent number: 9744155
    Abstract: Indole-3-propionic acid as a marker and for treatment for Huntington Disease.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: August 29, 2017
    Assignee: IXCELA, INC.
    Inventor: Wayne Matson
  • Patent number: 9733261
    Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in stroke patients and in patients at risk for stroke. In particular, the invention relates to using assays that detect one or more biomarkers as diagnostic and prognostic biomarker assays in such patients.
    Type: Grant
    Filed: April 24, 2013
    Date of Patent: August 15, 2017
    Assignee: Astute Medical, Inc.
    Inventors: Joseph Anderberg, Jeff Gray, Paul McPherson, Kevin Nakamura, James Patrick Kampf
  • Patent number: 9694052
    Abstract: Preparations including FSH, for example recombinant FSH, for use in the treatment of infertility.
    Type: Grant
    Filed: August 8, 2012
    Date of Patent: July 4, 2017
    Assignee: Ferring B.V.
    Inventor: Joan-Carles Arce
  • Patent number: 9678085
    Abstract: Ligands that bind to prion proteins and methods for using the ligands for detecting or removing a prion protein from a sample, such as a biological fluid or an environmental sample. The ligands are capable of binding to one or more forms of prion protein including cellular prion protein (PrPc), infectious prion protein (PrPsc), and recombinant prion protein (PrPr). Prions from various species, including humans and hamsters, are bound by the ligands. Also provided is a method of treating or retarding the development of a prion-associated pathology in a subject.
    Type: Grant
    Filed: October 31, 2013
    Date of Patent: June 13, 2017
    Assignees: Pathogen Removal and Diagnostic Technologies Inc., North Carolina State University
    Inventors: David J. Hammond, Julia T. Lathrop, Larisa Cervenakova, Ruben G. Carbonell
  • Patent number: 9664688
    Abstract: A method for identifying a patient that is at risk for developing a thyroid disorder that occurs subsequent to treatment with a regimen that depletes lymphocytes, comprising determining whether antibodies directed against thyroid peroxidase or thyroid microsomes are present in the patient, wherein if the antibodies are present in the patient then the patient is at increased risk for developing a thyroid disorder. A particular embodiment is a method for identifying a patient with multiple sclerosis that is at risk for developing a thyroid disorder that occurs subsequent to treatment with a regimen that depletes CD52-positive cells, comprising determining whether antibodies directed against thyroid peroxidase or thyroid microsomes are present in the patient, wherein if the antibodies are present in the patient then the patient is at risk for developing the thyroid disorder.
    Type: Grant
    Filed: December 5, 2012
    Date of Patent: May 30, 2017
    Assignee: GENZYME CORPORATION
    Inventor: David H. Margolin
  • Patent number: 9651561
    Abstract: The technology described herein relates to KIM-1 and the diagnosis, prognosis, and treatment of endometrial diseases and disorders.
    Type: Grant
    Filed: November 13, 2013
    Date of Patent: May 16, 2017
    Assignee: The Brigham and Womens's Hospital, Inc.
    Inventors: Joseph V. Bonventre, Venkata Sabbisetti
  • Patent number: 9642913
    Abstract: A composition including a surfactant and at least one alkyl glycoside and/or saccharide alkyl ester and a drug. The surfactant composition(s) when admixed with a drug is non-toxic and non-irritating, while stabilizing and increasing the bioavailability of the drug. The invention also provides compositions that enhance absorption of drugs via the oral, ocular, nasal, nasolacrimal, inhalation or pulmonary, oral cavity (sublingual or Buccal cell) or CSF delivery route of a patient, including but not limited to insulin, glucagon and exendin-4.
    Type: Grant
    Filed: January 10, 2014
    Date of Patent: May 9, 2017
    Assignee: Aegis Therapeutics, LLC.
    Inventor: Edward T. Maggio
  • Patent number: 9636325
    Abstract: Indole-3-propionic acid as a marker and for treatment for Huntington Disease.
    Type: Grant
    Filed: April 16, 2015
    Date of Patent: May 2, 2017
    Assignee: IXCELA, INC.
    Inventor: Wayne R. Matson
  • Patent number: 9629827
    Abstract: The invention encompasses methods of decreasing the lumenal diameter of a blood vessel by contacting the vessel with a myosin light chain phosphatase inhibitor.
    Type: Grant
    Filed: November 9, 2010
    Date of Patent: April 25, 2017
    Assignee: WASHINGTON UNIVERSITY
    Inventor: Walter A. Boyle
  • Patent number: 9623044
    Abstract: The present invention relates to chitosan hydrogel microparticles of a median size d50 comprised between 1 and 500 ?m (obtained from a number distribution), the chitosan having a degree of acetylation of less than equal to 20% and its concentration in the hydrogel being comprised between 0.25 and 5% by weight based on a total weight of the hydrogel, for use in neuron regeneration and/or in the repair of the nervous system, advantageously of the central nervous system, and/or in the grafting of neurons and/or in the treatment of neurodegenerative diseases and/or in the treatment of paralyses. It also relates to an implant comprising an aqueous suspension of microparticles mixed with Schwann cells and/or stem cells and/or trophic factors.
    Type: Grant
    Filed: July 16, 2013
    Date of Patent: April 18, 2017
    Assignees: UNIVERSITE CLAUDE BERNARD LYON I, INSTITUT NATIONAL DES SCIENCES APPLIQUEES DE LYON, UNIVERSITE JEAN MONNET, SAINT ETIENNE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6)
    Inventors: Fatiha Nothias, Sylvia Soares, Laurent David, Alexandra Montembault
  • Patent number: 9603837
    Abstract: Indole-3-propionic acid as a marker and for treatment for Huntington Disease.
    Type: Grant
    Filed: November 27, 2013
    Date of Patent: March 28, 2017
    Assignee: IXCELA, INC.
    Inventor: Wayne R. Matson
  • Patent number: 9592258
    Abstract: Methods, pharmaceutical compositions and kits for regenerating or repairing neural tissue, decreasing apoptosis and improving neurological function following injury using human umbilical cord tissue-derived cells are disclosed.
    Type: Grant
    Filed: May 6, 2015
    Date of Patent: March 14, 2017
    Assignee: DePuy Synthes Products, Inc.
    Inventors: Agnieszka Seyda, Anna Gosiewska
  • Patent number: 9585935
    Abstract: The disclosure provides a method for enhancing memory of a subject, lowering blood glucose levels in a subject, and treating schizophrenia, the methods comprise intranasally administering to the subject an amount of a oxytocin peptide or analog thereof having a beneficial effect.
    Type: Grant
    Filed: July 30, 2011
    Date of Patent: March 7, 2017
    Assignee: The Regents of the University of California
    Inventor: David Feifel
  • Patent number: 9572865
    Abstract: In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density, as well as for the treatment of multiple myeloma.
    Type: Grant
    Filed: April 30, 2012
    Date of Patent: February 21, 2017
    Assignee: Acceleron Pharma Inc.
    Inventors: John Knopf, Jasbir Seehra, Ravindra Kumar
  • Patent number: 9567395
    Abstract: The present disclosure provides methods of treating a tauopathy, involving administering an anti-Tau antibody. The present disclosure also provides anti-Tau antibodies, and formulations comprising same, for use in the methods.
    Type: Grant
    Filed: August 15, 2013
    Date of Patent: February 14, 2017
    Assignee: IPIERIAN, INC.
    Inventors: Irene Griswold-Prenner, Nancy E. Stagliano, Vu Cao Dang